Raphael Pharmaceutical (RAPH) Net Cash Flow (2020 - 2025)
Raphael Pharmaceutical (RAPH) posted Net Cash Flow of $42000.0 for Q4 2025, up 347.06% sequentially from -$17000.0 in Q3 2025, and up 300.0% YoY from $10500.0 in Q4 2024.
Raphael Pharmaceutical (RAPH) Net Cash Flow (2020 - 2025) Analysis & Trends
Raphael Pharmaceutical has reported Net Cash Flow for 6 years, with the latest figure at $42000.0 in Q4 2025.
- Quarterly Net Cash Flow rose 300.0% year-over-year to $42000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $26000.0 (up 112.26% YoY) and the FY2025 annual result came in at $26000.0, up 112.32% from the prior year.
- Net Cash Flow advanced to $42000.0 in Q4 2025 per RAPH's latest filing, from -$17000.0 in the prior quarter.
- Over five years, Net Cash Flow peaked at $208000.0 in Q2 2021 and troughed at -$250000.0 in Q1 2023.
- A 5-year average of -$2450.0 and a median of -$19000.0 in 2024 frame the typical range for Net Cash Flow.
- The sharpest annual moves came in 2023 and 2024: Net Cash Flow surged 570.0% in 2023, then slumped 330.14% in 2024.
- Over 5 years, Net Cash Flow stood at $116000.0 in 2021, then soared by 68.1% to $195000.0 in 2022, then slumped by 135.38% to -$69000.0 in 2023, then soared by 69.57% to -$21000.0 in 2024, then jumped by 300.0% to $42000.0 in 2025.
- According to Business Quant data, Net Cash Flow over the past three periods registered $42000.0, -$17000.0, and -$30000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.91 Bn | 42.95 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.07 Bn | 39.42 Bn | 2.15 Bn | -81.00 Mn |
| 3 | Zoetis | 31.54 Bn | 29.86 Bn | 1.05 Bn | -458.00 Mn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | -881.03 Mn |
| 5 | United Therapeutics | 22.19 Bn | 19.53 Bn | 683.80 Mn | 523.50 Mn |
| 6 | Viatris | 18.68 Bn | 17.79 Bn | 1.46 Bn | -912.40 Mn |
| 7 | Neurocrine Biosciences | 15.50 Bn | 15.11 Bn | 935.80 Mn | 64.40 Mn |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn | 93.00 Mn |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.96 Bn | - | - |
| 10 | Raphael Pharmaceutical | 28.25 Mn | 28.25 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 42,000.00 |
| Dec 31, 2025 | 42,000.00 |
| Sep 30, 2025 | -17,000.00 |
| Sep 30, 2025 | -17,000.00 |
| Jun 30, 2025 | -30,000.00 |
| Jun 30, 2025 | -30,000.00 |
| Mar 31, 2025 | 31,000.00 |
| Mar 31, 2025 | 31,000.00 |
| Dec 31, 2024 | -21,000.00 |
| Dec 31, 2024 | -21,000.00 |
| Sep 30, 2024 | -80,000.00 |
| Sep 30, 2024 | -80,000.00 |
| Jun 30, 2024 | -168,000.00 |
| Jun 30, 2024 | -168,000.00 |
| Mar 31, 2024 | 57,000.00 |
| Mar 31, 2024 | 57,000.00 |
| Dec 31, 2023 | -69,000.00 |
| Dec 31, 2023 | -69,000.00 |
| Sep 30, 2023 | 188,000.00 |
| Sep 30, 2023 | 188,000.00 |